Search Result
Results for "
Cholangiocarcinoma
" in MedChemExpress (MCE) Product Catalog:
1
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-109099
-
Pemigatinib
Maximum Cited Publications
16 Publications Verification
INCB054828
|
FGFR
|
Cancer
|
|
Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor with IC50s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma .
|
-
-
- HY-14570
-
|
|
Apoptosis
|
Cancer
|
Triphen diol is a phenol diol derivative, which has excellent anticancer activity against pancreatic cancer and cholangiocarcinoma, and can induce pancreatic cell apoptosis through two mechanisms, caspase-mediated and caspase-independent .
|
-
-
- HY-P99134
-
|
|
c-Fms
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse GM-CSF Antibody (MP1-22E9) is a rat-derived anti-mouse GM-CSF IgG2a antibody inhibitor. Anti-Mouse GM-CSF Antibody (MP1-22E9) can neutralize GM-CSF. Anti-Mouse GM-CSF Antibody (MP1-22E9) can be used for the researches of cancer, infection inflammation and immunology, such as cholangiocarcinoma and arthritis .
|
-
-
- HY-N0819
-
|
|
Apoptosis
|
Cancer
|
|
Raddeanin A is a natural triterpenoid saponin component of Anemone raddeana, with anti-cancer activities. Raddeanin A exerts anticancer effect on human osteosarcoma via the ROS/JNK and NF-κB signal pathway .
|
-
-
- HY-109099R
-
|
INCB054828 (Standard)
|
Reference Standards
FGFR
|
Cancer
|
|
Pemigatinib (Standard) is the analytical standard of Pemigatinib. This product is intended for research and analytical applications. Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor with IC50s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma .
|
-
-
- HY-178120
-
|
|
Src
Apoptosis
|
Cancer
|
|
Lck-IN-4 (Compound A-1) is a protein tyrosine kinase Lck inhibitor with an IC50 of 2 nM. Lck-IN-4 significantly inhibits YAP tyrosine phosphorylation and activity and induces apoptosis in cholangiocarcinoma CCA cells. Lck-IN-4 is cytotoxic in CCA tumor-derived organoids with elevated YAP activity Lck-IN-4 can be used for cancers like cholangiocarcinoma (CCA) research .
|
-
-
- HY-175743
-
|
|
FGFR
|
Cancer
|
|
TYRA-200 is an orally active FGFR1/2/3 inhibitor. TYRA-200 shows dose-dependent tumor regression in both wild-type FGFR2 and FGFR2 mutant mice model. TYRA-200 can be used for advanced or metastatic intrahepatic cholangiocarcinoma and other FGFR2-driven solid tumors research .
|
-
-
- HY-N15136
-
|
|
Apoptosis
|
Cancer
|
|
Isomorellinol is a xanthone with an anticancer potency. Isomorellinol induces apoptosis in cholangiocarcinoma cells. Isomorellinol increases the Bax/Bcl-2 protein expression ratio and decreases survivin protein expression in cholangiocarcinoma cells .
|
-
-
- HY-N0819R
-
|
|
Apoptosis
|
Cancer
|
|
Raddeanin A is a natural triterpenoid saponin component of Anemone raddeana, with anti-cancer activities. Raddeanin A exerts anticancer effect on human osteosarcoma via the ROS/JNK and NF-κB signal pathway .
|
-
-
- HY-E70827
-
|
|
FGFR
|
Cancer
|
|
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 V564L is a mutant of FGFR3. FGFR2 V564L Recombinant Human Active Protein Kinase is a recombinant FGFR2 V564L protein that can be used to study FGFR2 V564L-related functions .
|
-
-
- HY-W754878
-
|
INCB054828-d6
|
Isotope-Labeled Compounds
FGFR
|
Cancer
|
|
Pemigatinib-d6 (INCB054828-d6) is deuterium labeled Pemigatinib. Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor with IC50s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma .
|
-
-
- HY-E70818
-
|
|
FGFR
|
Cancer
|
|
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 K659M is a mutant of FGFR3. FGFR2 K659M Recombinant Human Active Protein Kinase is a recombinant FGFR2 K659M protein that can be used to study FGFR2 K659M-related functions .
|
-
-
- HY-E70823
-
|
|
FGFR
|
Cancer
|
|
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 N549K is a mutant of FGFR3. FGFR2 N549K Recombinant Human Active Protein Kinase is a recombinant FGFR4 N535K protein that can be used to study FGFR4 N535K-related functions .
|
-
-
- HY-E70815
-
|
|
FGFR
|
Cancer
|
|
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 K526E is a mutant of FGFR3. FGFR2 K526E Recombinant Human Active Protein Kinase is a recombinant FGFR2 K526E protein that can be used to study FGFR2 K526E-related functions .
|
-
-
- HY-E70825
-
|
|
FGFR
|
Cancer
|
|
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 V564F is a mutant of FGFR3. FGFR2 V564F Recombinant Human Active Protein Kinase is a recombinant FGFR2 V564F protein that can be used to study FGFR2 V564F-related functions .
|
-
-
- HY-E70826
-
|
|
FGFR
|
Cancer
|
|
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 V564I is a mutant of FGFR3. FGFR2 V564I Recombinant Human Active Protein Kinase is a recombinant FGFR2 V564I protein that can be used to study FGFR2 V564I-related functions .
|
-
-
- HY-E70814
-
|
|
FGFR
|
Cancer
|
|
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 C491S is a mutant of FGFR3. FGFR2 C491S Recombinant Human Active Protein Kinase is a recombinant FGFR2 C491S protein that can be used to study FGFR2 C491S-related functions .
|
-
-
- HY-E70817
-
|
|
FGFR
|
Cancer
|
|
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 K641R is a mutant of FGFR3. FGFR2 K641R Recombinant Human Active Protein Kinase is a recombinant FGFR2 K641R protein that can be used to study FGFR2 K641R-related functions .
|
-
-
- HY-E70822
-
|
|
FGFR
|
Cancer
|
|
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 N549H is a mutant of FGFR3. FGFR2 N549H Recombinant Human Active Protein Kinase is a recombinant FGFR4 N535H protein that can be used to study FGFR4 N535H-related functions .
|
-
-
- HY-E70820
-
|
|
FGFR
|
Cancer
|
|
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 L617V is a mutant of FGFR3. FGFR2 L617V Recombinant Human Active Protein Kinase is a recombinant FGFR2 L617V protein that can be used to study FGFR2 L617V-related functions .
|
-
-
- HY-E70821
-
|
|
FGFR
|
Cancer
|
|
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 M537I is a mutant of FGFR3. FGFR2 M537I Recombinant Human Active Protein Kinase is a recombinant FGFR2 M537I protein that can be used to study FGFR2 M537I-related functions .
|
-
-
- HY-E70824
-
|
|
FGFR
|
Cancer
|
|
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 R612T is a mutant of FGFR3. FGFR2 R612T Recombinant Human Active Protein Kinase is a recombinant FGFR2 R612T protein that can be used to study FGFR2 R612T-related functions .
|
-
-
- HY-E70819
-
|
|
FGFR
|
Cancer
|
|
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 K659N is a mutant of FGFR3. FGFR2 K659N Recombinant Human Active Protein Kinase is a recombinant FGFR2 K659N protein that can be used to study FGFR2 K659N-related functions .
|
-
-
- HY-E70816
-
|
|
FGFR
|
Cancer
|
|
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 K641N is a mutant of FGFR3. FGFR2 K641N Recombinant Human Active Protein Kinase is a recombinant FGFR2 K641N protein that can be used to study FGFR2 K641N-related functions .
|
-
-
- HY-113308
-
|
|
Calcium Channel
Endogenous Metabolite
|
Others
|
|
Taurolithocholic acid is a bile acid that has the activity of increasing cell viability, inducing the S phase of the cell cycle, and promoting DNA synthesis in a concentration-dependent manner in the intrahepatic cholangiocarcinoma cell line RMCCA-1. It can also increase the phosphorylation of EGFR and ERK 1/2 and the expression of cyclin D1 in RMCCA-1 cells, and its induced RMCCA-1 cell growth can be inhibited by specific antagonists and inhibitors.
|
-
-
- HY-174154
-
|
|
FGFR
|
Cancer
|
|
INCB126503 is an orally activeM, selective FGFR2/3 Inhibitor with IC50 values of 70 nM (FGFR1), 2.1 nM (FGFR2), 1.2 nM (FGFR3), 0.92 nM (FGFR3-V555L), 0.85 nM (FGFR3-V555M) and 64 nM (FGFR4). INCB126503 suppresses FGFR signaling in vivo without causing hyperphosphatemia and shows antitumor efficacy in xenograft models harboring FGFR3 genetic alterations .
|
-
-
- HY-E70618
-
|
|
E1/E2/E3 Enzyme
|
Cancer
|
|
Ubiquitin Conjugating enzyme E2C (EC 2.3.2.24) is a member of the E2 ubiquitin-conjugating enzyme family, and it is the principal regulator of pathways for protein degradation in eukaryotes. Ubiquitin Conjugating enzyme E2C is involved in the tumorigenesis of various malignancies. Ubiquitin Conjugating enzyme E2C is also involved in mitotic cyclin disruption, affecting cell cycle progression. Ubiquitin Conjugating enzyme E2C is a prognostic indicator for cholangiocarcinoma .
|
-
-
- HY-156632
-
|
KIN-3248
|
FGFR
|
Cancer
|
|
Resigratinib (KIN-3248) is an irreversible and orally active covalent inhibitor of FGFR1-4 that effectively inhibits wild-type and drug-resistant mutations (such as FGFR2 V565F, FGFR3 V555M). Resigratinib covalently binds to the Cys492 site of FGFR, blocks the FGFR signaling pathway, inhibits tumor cell proliferation and induces apoptosis. Resigratinib can be used for the study of FGFR2/3-driven solid tumors (such as cholangiocarcinoma and bladder cancer) .
|
-
-
- HY-160929
-
-
-
- HY-P99463
-
|
AVB-500; AVB-S6-500
|
TAM Receptor
PI3K
Akt
p38 MAPK
|
Cancer
|
|
Batiraxcept (AVB-500; AVB-S6-500) is a selective, soluble AXL receptor and GAS6 inhibitor that targets the GAS6-AXL signaling axis. Batiraxcept is orally inactive and does not cross the blood-brain barrier. Batiraxcept competitively binds to GAS6 ((KD <1 nM), preventing its interaction with the AXL receptor tyrosine kinase, thereby inhibiting downstream PI3K/AKT and MAPK signaling pathways, reducing tumor cell glycolysis, angiogenesis, and metastatic potential. Batiraxcept has demonstrated antitumor activity in preclinical models of endometrial, cholangiocarcinoma, and ovarian cancer by inhibiting tumor growth, invasion, and metastasis .
|
-
-
- HY-175700
-
|
|
Topoisomerase
Apoptosis
|
Cancer
|
|
YCJ-02 is a selective Topoisomerase I (Top I) inhibitor. YCJ-02 can inhibit cell proliferation and induce apoptosis and G2/M phase arrest. YCJ-02 can induce DNA damage and increaseγ-H2AX levels. YCJ-02 can promote Top I deqradation via a ubiquitin/26S proteasome pathway. YCJ-02 increases the expressions of pro-apoptotic proteins Bad, Bax, and cleaved
caspase-3. YCJ-02 shows broad-spectrum antitumor activity. YCJ-02 can be used for the research of cancer, such as intrahepatic cholangiocarcinoma (ICC) .
|
-
-
- HY-W040129
-
|
|
DNA Alkylator/Crosslinker
DNA/RNA Synthesis
Apoptosis
Caspase
|
Infection
Neurological Disease
Cancer
|
|
Chromomycin A3 is an inhibitor that selectively binds to GC-rich DNA sequences. Chromomycin A3 targets the DNA minor groove after forming a dimer with Mg 2+. Chromomycin A3 inhibits DNA replication and transcription, blocks the binding of Sp1 transcription factor to target gene promoters, downregulates the expression of anti-apoptotic proteins such as FLIP, Mcl-1, and XIAP, and induces S-phase cycle arrest and caspase-dependent apoptosis in tumor cells. Chromomycin A3 can antagonize oxidative stress induced by glutathione depletion and neuronal apoptosis induced by Camptothecin (HY-15660). Chromomycin A3 can be used in basic research on malignant tumors such as cholangiocarcinoma, and is a potential chemosensitizer and GC-rich region probe .
|
-
-
- HY-W040129R
-
|
|
Reference Standards
Bacterial
Fungal
Apoptosis
Antibiotic
|
Infection
Neurological Disease
Cancer
|
|
Chromomycin A3 (Standard) is the analytical standard of Chromomycin A3 (HY-W040129). This product is intended for research and analytical applications. Chromomycin A3 is an inhibitor that selectively binds to GC-rich DNA sequences. Chromomycin A3 targets the DNA minor groove after forming a dimer with Mg 2+. Chromomycin A3 inhibits DNA replication and transcription, blocks the binding of Sp1 transcription factor to target gene promoters, downregulates the expression of anti-apoptotic proteins such as FLIP, Mcl-1, and XIAP, and induces S-phase cycle arrest and caspase-dependent apoptosis in tumor cells. Chromomycin A3 can antagonize oxidative stress induced by glutathione depletion and neuronal apoptosis induced by Camptothecin (HY-15660). Chromomycin A3 can be used in basic research on malignant tumors such as cholangiocarcinoma, and is a potential chemosensitizer and GC-rich region probe .
|
-
-
- HY-16138
-
|
CG-200745
|
HDAC
MDM-2/p53
Apoptosis
|
Cancer
|
|
Ivaltinostat (CG-200745) is an orally active, potent pan-HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat inhibits deacetylation of histone H3 and tubulin. Ivaltinostat induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of MDM2 and p21 (Waf1/Cip1) proteins. Ivaltinostat enhances the sensitivity of Gemcitabine-resistant cells to Gemcitabine (HY-16138) and 5-Fluorouracil (5-FU; HY-90006). Ivaltinostat induces apoptosis and has anti-tumour effects .
|
-
-
- HY-16138A
-
|
CG-200745 formic
|
HDAC
MDM-2/p53
Apoptosis
|
Inflammation/Immunology
Endocrinology
Cancer
|
|
Ivaltinostat (CG-200745) formic is an orally active, potent pan-HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat formic inhibits deacetylation of histone H3 and tubulin. Ivaltinostat formic induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of MDM2 and p21 (Waf1/Cip1) proteins. Ivaltinostat formic enhances the sensitivity of Gemcitabine-resistant cells to Gemcitabine (HY-16138) and 5-Fluorouracil (5-FU; HY-90006). Ivaltinostat formic induces apoptosis and has anti-tumour effects .
|
-
-
- HY-149486
-
|
|
FGFR
|
Cancer
|
|
FGFR1 inhibitor 7 (compound 5) is an inhibitor of FGFR1 Tyrosine Kinase with IC50 value of 0.33 nM. FGFR1 inhibitor 7 shows broad-spectrum cytotoxicity agasinst human cancer cell lines, and inhibits MOLT3 cells with IC50 of 2.1 μM .
|
-
-
- HY-K6106
-
|
|
|
MCE Human Cholangiocarcinoma Organoid Kit contains Cholangiocarcinoma Organoid Basal Medium A, Cholangiocarcinoma Organoid Supplement B (50×), Cholangiocarcinoma Organoid Supplement C (250×). This product can be used to efficiently construct human cholangiocarcinoma organoid.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99134
-
|
|
c-Fms
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse GM-CSF Antibody (MP1-22E9) is a rat-derived anti-mouse GM-CSF IgG2a antibody inhibitor. Anti-Mouse GM-CSF Antibody (MP1-22E9) can neutralize GM-CSF. Anti-Mouse GM-CSF Antibody (MP1-22E9) can be used for the researches of cancer, infection inflammation and immunology, such as cholangiocarcinoma and arthritis .
|
-
- HY-P99463
-
|
AVB-500; AVB-S6-500
|
TAM Receptor
PI3K
Akt
p38 MAPK
|
Cancer
|
|
Batiraxcept (AVB-500; AVB-S6-500) is a selective, soluble AXL receptor and GAS6 inhibitor that targets the GAS6-AXL signaling axis. Batiraxcept is orally inactive and does not cross the blood-brain barrier. Batiraxcept competitively binds to GAS6 ((KD <1 nM), preventing its interaction with the AXL receptor tyrosine kinase, thereby inhibiting downstream PI3K/AKT and MAPK signaling pathways, reducing tumor cell glycolysis, angiogenesis, and metastatic potential. Batiraxcept has demonstrated antitumor activity in preclinical models of endometrial, cholangiocarcinoma, and ovarian cancer by inhibiting tumor growth, invasion, and metastasis .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N0819
-
-
-
- HY-W040129
-
|
|
Microorganisms
Source classification
|
DNA Alkylator/Crosslinker
DNA/RNA Synthesis
Apoptosis
Caspase
|
|
Chromomycin A3 is an inhibitor that selectively binds to GC-rich DNA sequences. Chromomycin A3 targets the DNA minor groove after forming a dimer with Mg 2+. Chromomycin A3 inhibits DNA replication and transcription, blocks the binding of Sp1 transcription factor to target gene promoters, downregulates the expression of anti-apoptotic proteins such as FLIP, Mcl-1, and XIAP, and induces S-phase cycle arrest and caspase-dependent apoptosis in tumor cells. Chromomycin A3 can antagonize oxidative stress induced by glutathione depletion and neuronal apoptosis induced by Camptothecin (HY-15660). Chromomycin A3 can be used in basic research on malignant tumors such as cholangiocarcinoma, and is a potential chemosensitizer and GC-rich region probe .
|
-
-
- HY-N15136
-
-
-
- HY-N0819R
-
-
-
- HY-W040129R
-
|
|
Microorganisms
Source classification
|
Reference Standards
Bacterial
Fungal
Apoptosis
Antibiotic
|
|
Chromomycin A3 (Standard) is the analytical standard of Chromomycin A3 (HY-W040129). This product is intended for research and analytical applications. Chromomycin A3 is an inhibitor that selectively binds to GC-rich DNA sequences. Chromomycin A3 targets the DNA minor groove after forming a dimer with Mg 2+. Chromomycin A3 inhibits DNA replication and transcription, blocks the binding of Sp1 transcription factor to target gene promoters, downregulates the expression of anti-apoptotic proteins such as FLIP, Mcl-1, and XIAP, and induces S-phase cycle arrest and caspase-dependent apoptosis in tumor cells. Chromomycin A3 can antagonize oxidative stress induced by glutathione depletion and neuronal apoptosis induced by Camptothecin (HY-15660). Chromomycin A3 can be used in basic research on malignant tumors such as cholangiocarcinoma, and is a potential chemosensitizer and GC-rich region probe .
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-W754878
-
|
|
|
Pemigatinib-d6 (INCB054828-d6) is deuterium labeled Pemigatinib. Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor with IC50s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
